Protective role of metalloproteinase inhibitor (AE-941) on ulcerative colitis in rats

World Journal of Gastroenterology

Volumn 18, Issue 47, 2012, Pages 7063-7069

  Mao, Jing Wei ^a   He, Xiao Mei ^a   Tang, Hai Ying ^a   Wang, Ying De ^a  

^a DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

AE 941; Extracellular matrix; Matrix metalloproteinase 2; Matrix metalloproteinase 9; Ulcerative colitis

Indexed keywords

AE 941; ALCOHOL; GELATINASE A; GELATINASE B; MESSENGER RNA; TRINITROBENZENESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON MUCOSA; CONTROLLED STUDY; DISEASE ACTIVITY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; STOMACH LAVAGE; ULCERATIVE COLITIS;

EID: 84873897975     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i47.7063     Document Type: Article

References (26)

1. Lakatos G, Sipos F, Miheller P, Hritz I, Varga MZ, Juhász M, Molnár B, Tulassay Z, Herszényi L. The behavior of matrix metalloproteinase-9 in lymphocytic colitis, collagenous coli-tis and ulcerative colitis. Pathol Oncol Res 2012; 18: 85-91
2. Gao Q, Meijer MJ, Kubben FJ, Sier CF, Kruidenier L, van Duijn W, van den Berg M, van Hogezand RA, Lamers CB, Verspaget HW. Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases. Dig Liver Dis 2005; 37: 584-592
3. Meijer MJ, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, Hommes DW, Verspaget HW. Role of matrix metalloproteinase, tissue inhibitor of metalloproteinase and tumor necrosis factor-alpha single nucleotide gene polymorphisms in inflammatory bowel disease. World J Gastroenterol 2007; 13: 2960-2966
4. Mäkitalo L, Kolho KL, Karikoski R, Anthoni H, SaarialhoKere U. Expression profiles of matrix metalloproteinases and their inhibitors in colonic inflammation related to pediatric inflammatory bowel disease. Scand J Gastroenterol 2010; 45: 862-871
5. Gingras D, Boivin D, Deckers C, Gendron S, Barthomeuf C, Béliveau R. Neovastat--a novel antiangiogenic drug for cancer therapy. Anticancer Drugs 2003; 14: 91-96
6. Porter SN, Howarth GS, Butler RN. An orally administered growth factor extract derived from bovine whey suppresses breath ethane in colitic rats. Scand J Gastroenterol 1998; 33: 967-974
7. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SG, Van Rees EP. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol 1998; 114: 385-391
8. Wang YD, Yan PY. Expression of matrix metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in ulcerative colitis. World J Gastroenterol 2006; 12: 6050-6053
9. Wang YD, Mao JW. Expression of matrix metalloproteinase-1 and tumor necrosis factor-alpha in ulcerative colitis. World J Gastroenterol 2007; 13: 5926-5932
10. Zhang C, Kim SK. Matrix metalloproteinase inhibitors (MMPIs) from marine natural products: the current situation and future prospects. Mar Drugs 2009; 7: 71-84
11. Naito Y, Yoshikawa T. Role of matrix metalloproteinases in inflammatory bowel disease. Mol Aspects Med 2005; 26: 379-390
12. Ohbayashi H. Matrix metalloproteinases in lung diseases. Curr Protein Pept Sci 2002; 3: 409-421
13. von Lampe B, Barthel B, Coupland SE, Riecken EO, Rosewicz S. Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut 2000; 47: 63-73
14. Pirilä E, Ramamurthy NS, Sorsa T, Salo T, Hietanen J, Maisi P. Gelatinase A (MMP-2), collagenase-2 (MMP-8), and laminin-5 gamma2-chain expression in murine inflammatory bowel disease (ulcerative colitis). Dig Dis Sci 2003; 48: 93-98
15. Medina C, Videla S, Radomski A, Radomski MW, Antolín M, Guarner F, Vilaseca J, Salas A, Malagelada JR. Increased activity and expression of matrix metalloproteinase-9 in a rat model of distal colitis. Am J Physiol Gastrointest Liver Physiol 2003; 284: G116-G122
16. Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): Positive and negative regulators in tumor cell adhesion. Semin Cancer Biol 2010; 20: 161-168
17. Clutterbuck AL, Asplin KE, Harris P, Allaway D, Mobasheri A. Targeting matrix metalloproteinases in inflammatory conditions. Curr Drug Targets 2009; 10: 1245-1254
18. Wang YD, Wang W. Protective effect of ilomastat on trinitrobenzenesulfonic acid-induced ulcerative colitis in rats. World J Gastroenterol 2008; 14: 5683-5688
19. Wang YD, Tan XY, Zhang K. Correlation of plasma MMP-1 and TIMP-1 levels and the colonic mucosa expressions in patients with ulcerative colitis. Mediators Infamm 2009; 2009: 275072
20. Dredge K. AE-941 (AEterna). Curr Opin Investig Drugs 2004; 5: 668-677
21. Gingras D, Nyalendo C, Di Tomasso G, Annabi B, Béliveau R. Activation of tissue plasminogen activator gene transcription by Neovastat, a multifunctional antiangiogenic agent. Biochem Biophys Res Commun 2004; 320: 205-212
22. Béliveau R, Gingras D, Kruger EA, Lamy S, Sirois P, Simard B, Sirois MG, Tranqui L, Baffert F, Beaulieu E, Dimitriadou V, Pépin MC, Courjal F, Ricard I, Poyet P, Falardeau P, Figg WD, Dupont E. The antiangiogenic agent neovastat (AE-941) inhibits vascular endothelial growth factor-mediated biological effects. Clin Cancer Res 2002; 8: 1242-1250
23. Falardeau P, Champagne P, Poyet P, Hariton C, Dupont E. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials. Semin Oncol 2001; 28: 620-625
24. Gingras D, Renaud A, Mousseau N, Beaulieu E, Kachra Z, Béliveau R. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 2001; 21: 145-155
25. Latreille J, Batist G, Laberge F, Champagne P, Croteau D, Falardeau P, Levinton C, Hariton C, Evans WK, Dupont E. Phase I/II trial of the safety and effcacy of AE-941 (Neovastat) in the treatment of non-small-cell lung cancer. Clin Lung Cancer 2003; 4: 231-236
26. Escudier B, Choueiri TK, Oudard S, Szczylik C, Négrier S, Ravaud A, Chevreau C, Venner P, Champagne P, Croteau D, Dupont E, Hariton C, Bukowski RM. Prognostic factors of metastatic renal cell carcinoma after failure of immunotherapy: new paradigm from a large phase III trial with shark cartilage extract AE 941. J Urol 2007; 178: 1901-1905